Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.

Shares of biotech company CSL plunged after the company announced that Chief Executive Officer Paul McKenzie will step down.

The ASX 200 closed slightly lower, and the CSL chief executive stepped down abruptly ahead of tomorrow's half-year results. Catch up on the day's events and insights from our business reporters on the ...

Australia's CSL said on Wednesday it has granted Eli Lilly certain rights to develop and commercialize clazakizumab, an ...

Eli Lilly & CSL seal a deal for clazakizumab partitions rights to maximize lifecycle value. CSL retains ESKD focus as Lilly ...

SYDNEY—Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.

And this 3.0 CSL is something unique. It’s a total departure from BMW’s standard operating procedure. Hand-built by a team of 30 people, the 3.0 CSL runs through eight production stations and assembly ...

Exclusive licensing grants Lilly development and commercialization rights for clazakizumab beyond ESKD-related cardiovascular prevention, while CSL retains the ESKD cardiovascular events indication.

Australian biotech CSL Limited has entered into an exclusive licensing agreement with US pharma major Eli Lilly granting the latter certain rights to develop and commercialize clazakizumab, an ...

Feb ⁠18 (Reuters) - ⁠Australia's CSL said on Wednesday ​it had entered ​into an exclusive ⁠licensing ⁠agreement with ⁠Eli Lilly ​and Co, granting it ​certain ⁠rights to develop ⁠and commercialise ...

Earlier this year, BMW debuted the M4 CS, a car designed to sit between the Competition Package and the ultra-hardcore M4 GTS. Of course, bringing back the CS designation, which stands for Coupe Sport ...